Saudi Press

Saudi Arabia and the world
Wednesday, Jul 23, 2025

Efficacy of Pfizer’s Covid-19 pill questioned

Efficacy of Pfizer’s Covid-19 pill questioned

An Israeli study has indicated the medication is of little measurable benefit to patients in the 40-65 age bracket
A Covid-19 pill lauded by the World Health Organization (WHO) may be of little or no benefit to patients aged between 40 and 65, a new study by Israeli researchers has suggested. The medication, made by Pfizer and sold under the trade name Paxlovid, has proven effective in those aged over 65, however.

Published in the New England Journal of Medicine on Wednesday, the study involved 109,000 patients who had received Paxlovid. After analyzing different age brackets, the scientists concluded that the treatment did little to improve the conditions of patients aged 40 to 65. At the same time, the medication reduced the number of hospitalizations among seniors by approximately 75%, if given shortly after contracting Covid-19.

The analysis, however, is based on data obtained from the Israeli health system as opposed to observing patients in a randomized study with a control group – something which represents a departure from practices held as the standard for such research, AP pointed out.

No official comment from Pfizer has been forthcoming as of yet.

The US Food and Drug Administration authorized Paxlovid late last year for adults and children over 12 who suffer from chronic conditions like obesity, diabetes and heart disease. According to federal records cited by AP, over 3.9 million prescriptions for the medication have been issued since the drug was given the green light.

The Biden administration has been placing particular emphasis on Paxlovid in the hope of reducing the number of hospitalizations. US authorities are said to have shelled out some $10 billion to procure the drug, which is being made available to the public at thousands of pharmacies through the government’s test-and-treat initiative.

In an emailed statement on Wednesday, White House spokesperson Kevin Munoz cited several other studies which indicate that Paxlovid helps reduce hospitalizations among people 50 and older. That research, however, has yet to be published in peer-reviewed journals, AP noted.

The official was quoted as saying that the “growing body of evidence is showing that individuals between the ages of 50 and 64 can also benefit from Paxlovid.”
Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
AI Raises Alarms Over Long-Term Job Security
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Russia Formally Recognizes Taliban Government in Afghanistan
Mediators Edge Closer to Israel-Hamas Ceasefire Agreement
Emirates Airline Expands Market Share with New $20 Million Campaign
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
Amazon Reaches Major Automation Milestone with Over One Million Robots
Meta Announces Formation of Ambitious AI Unit, Meta Superintelligence Labs
China Unveils Miniature Insect-Like Surveillance Drone
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Iran Executes Alleged Israeli Spies and Arrests Hundreds Amid Post-War Crackdown
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
Iran's Parliament Votes to Suspend Cooperation with Nuclear Watchdog
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
NATO Leaders Endorse Plan for Increased Defence Spending
U.S. Crude Oil Prices Drop Below $65 Amid Market Volatility
Explosions Rock Doha as Iranian Missiles Target Qatar
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Oman Set to Introduce Personal Income Tax, First in Gulf
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Iran Intensifies Crackdown on Alleged Mossad Operatives After Sabotage Claims
Trump Praises Iran’s ‘Very Weak’ Response After U.S. Strikes and Presses Israel to Pursue Peace
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
G7 Leaders Fail to Reach Consensus on Key Global Issues
Mass exodus in Tehran as millions try to flee following Trump’s evacuation order
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
×